European CHMP recommends approval of azacytidine (Onureg) for maintenance treatment of acute myeloid leukaemia

Azacitidine, similar to cytidine, exerts its antineoplastic effects by multiple mechanisms, including cytotoxicity on cells in the bone marrow and hypomethylation of DNA. It has been reported to improve overall survival in acute myeloid leukaemia.

European Medicines Agency